ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO206

Study of Relationship Between Etiology of ESRD and Cancer Incidence in Chronic Hemodialysis Patients

Session Information

  • Onco-Nephrology: Clinical
    November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Onco-Nephrology

  • 1500 Onco-Nephrology


  • Feldman, Leonid, Wolfson Medical Center, Holon, Israel
  • Katkov, Anna, Wolfson Medical Center, Holon, Israel
  • Merkin, Lusia, Tel Aviv University, Tel Aviv, Israel
  • Haimov, Marieta, Wolfson Medical Center, Holon, Israel
  • Barnea, Zvi, Wolfson Medical Center, Holon, Israel
  • Cernes, Relu, Wolfson Medical Center, Holon, Israel
  • Brenner, Ronen, Tel Aviv University, Tel Aviv, Israel

Previous research has shown that patients with end-stage renal disease (ESRD) treated with dialysis are at increased risk of cancer development.The aim of the present study was to examine a relationship between etiology of ESRD and cancer incidence in patients treated with chronic hemodialysis (HD).


We conducted a retrospective study of the cohort of hemodialysis patients over the age of 18 treated at teaching hospital between 2008 and 2017. Patients diagnosed with cancer prior to dialysis or with history of transplantation were excluded. Data on cancer diagnoses in the cohort population was collected from the National Cancer Registry. A multivariate analysis was conducted to examine the relationship between the various predictors and the incidence of cancer.


The study included 333 patients, of whom 211 (63.4%) were males. The mean age at start of HD was 67.2±13.1 years. The etiology of ESRD was diabetes in 41%, hypertension in 31%, glomerulonephritis in 7%, cystic kidney disease in 5% and nephrolithiasis in 3% of cases. The median follow-up time was 4 (95%CI, 2.0-6.5) years. 28 patients (8.4%) developed 30 cases of primary malignancy during treatment with hemodialysis. The most common site of cancer was colon (33.3% of cases), followed by bladder (16.7%), kidney (10%) and prostate (10%). Higher patients' age was associated with cancer development: 72.3±7.7 years in patients that developed and 66.7±13.4 years in those that did not develop cancer (p=0.001). No statistically significant relationship was found between ESRD etiology and occurrence of malignancy.


We did not found association between ESRD etiology and cancer incidence in our cohort of hemodialysis patients.